Neriforte (Diflucortolone Valerate)

Diflucortolone valerate penetrates the skin and binds to glucocorticoid receptors inside cells. The resulting complex alters gene transcription, increasing anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines. This cascade reduces leukocyte migration, vascular dilation and the release of mediators that cause skin inflammation and pruritus.

The specific dose and frequency of Neriforte are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient age. Typically, a thin layer is applied to the affected area once or twice daily for the period recommended by the healthcare professional.

Safety data for diflucortolone valerate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To request Neriforte, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Neriforte (diflucortolone valerate) is classified as a high‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑ to medium‑potency agents such as hydrocortisone. Compared with other high‑potency steroids, its efficacy is comparable, but the safety profile and risk of systemic absorption depend on the treated area, duration of use and occlusion.

Store Neriforte at room temperature, preferably below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures. Keep the packaging tightly closed and out of reach of children.

Neriforte is applied topically to clean, dry skin. Use a thin film and gently rub it in until fully absorbed. Avoid contact with eyes, mucous membranes and broken skin unless directed by a physician. Wash hands after application unless the hands are the treatment site.

Serious adverse effects include skin atrophy, telangiectasia, secondary infections and, rarely, systemic adrenal suppression when large areas are treated for prolonged periods. If signs of severe thinning, bruising, unexplained fatigue or hormonal disturbances appear, discontinue use and seek medical attention promptly.

Neriforte should be avoided in patients with known hypersensitivity to diflucortolone valerate or any excipients, in untreated bacterial, viral or fungal skin infections, and in individuals with severe skin atrophy or systemic conditions that contraindicate corticosteroid therapy unless specifically advised by a physician.